284
Views
6
CrossRef citations to date
0
Altmetric
Review

The independent relationship between triglycerides and coronary heart disease

&
Pages 89-95 | Published online: 28 Dec 2022

Abstract

Aims:

The aim was to review epidemiologic studies to reassess whether serum levels of triglycerides should be considered independently of high-density lipoprotein-cholesterol (HDL-C) as a predictor of coronary heart disease (CHD).

Methods and results:

We systematically reviewed population-based cohort studies in which baseline serum levels of triglycerides and HDL-C were included as explanatory variables in multivariate analyses with the development of CHD (coronary events or coronary death) as dependent variable. A total of 32 unique reports describing 38 cohorts were included. The independent association between elevated triglycerides and risk of CHD was statistically significant in 16 of 30 populations without pre-existing CHD. Among populations with diabetes mellitus or pre-existing CHD, or the elderly, triglycerides were not significantly independently associated with CHD in any of 8 cohorts. Triglycerides and HDL-C were mutually exclusive predictors of coronary events in 12 of 20 analyses of patients without pre-existing CHD.

Conclusions:

Epidemiologic studies provide evidence of an association between triglycerides and the development of primary CHD independently of HDL-C. Evidence of an inverse relationship between triglycerides and HDL-C suggests that both should be considered in CHD risk estimation and as targets for intervention.

Introduction

Serum cholesterol levels are important components of guidelines for determining risk and treatment of coronary heart disease (CHD). Low-density lipoprotein-cholesterol (LDL-C), the primary component of total cholesterol, is recognized as the most important lipid risk factor. Cardiovascular risk assessment in US and UK guidelines is based on the Framingham algorithm, in which the 10-year risk of CHD is calculated from levels of total cholesterol and high-density lipoprotein-cholesterol (HDL-C), and from demographic and clinical factors.Citation1,Citation2 Serum triglyceride levels are not a factor in quantifying CHD risk in these guidelines. A different basis for cardiovascular risk assessment has been adopted by the joint European societies.Citation3 European guidelines base their treatment recommendations on the ten-year risk of coronary death, which is calculated from the plasma level of total cholesterol and nonlipid risk factors.Citation4,Citation5 Both the UK and European guidelines, however, recognize that elevated triglycerides increase the risk of CHD.Citation5Citation7

Triglycerides do appear in international guidelines in considering therapy. Hypertriglyceridemia is recognized as a therapeutic target in UK guidelines. In European and US guidelines, combined elevated triglycerides and low HDL-C are to be considered when deciding on therapy.

The position of triglycerides in the guidelines is largely secondary to that of HDL-C. Given that the relationship between triglycerides and CHD is based on epidemiological studies, the objective here was to review the literature describing those studies to reassess whether triglycerides should be considered independently of HDL-C as a predictor of CHD and target for treatment.

Methods

Articles describing population-based cohort studies were identified in a February 2008 update of searches described in published meta-analyses.Citation8Citation10 Articles were included in this literature review if they met the following criteria: cohort study of risk of cardiovascular disease; measurement of triglycerides at baseline; a multiple regression analysis of the independent association between triglycerides and risk of CHD, with HDL-C as an explanatory variable; article published in the peer-reviewed literature; and article in English. A total of 46 articles met these inclusion criteria.Citation11Citation56 To avoid double counting, we considered only one analysis of any cohort (except for subpopulations) – typically the most recent publication meeting the inclusion criteria. Multiple articles reporting the Copenhagen Male Study (CMS),Citation28Citation30 Caerphilly and Speedwell Collaborative Heart Disease Studies (CSCHDS),Citation15,Citation52 Framingham Heart Study (FHS; for men but not women),Citation20,Citation51 Prospective Cardiovascular Münster Study (PROCAM),Citation12Citation14 Lipid Research Clinics Prevalence and Mortality Follow-Up Study (LRC-FS),Citation11,Citation19 Nurses’ Health Study (NHS),Citation43,Citation44 and occupational groups examined in Rome (ROG)Citation35,Citation36 cohorts typically agreed on the study result (significance of the association between triglycerides and CHD) or reached a consensus. Two reports of the Multiple Risk Factor Intervention Trial (MRFIT) study disagreed, however: the 25-year follow-up analysis reported a significant association, whereas a 6.1-year follow-up did not (the article reporting the 25-year follow-up was used for the MRFIT study).Citation11,Citation22 After excluding duplicate reports of the same cohort, a report in which the outcome was all-cause deaths,Citation24 and a report in which the outcome was heart failure,Citation26 32 reports with coronary events or coronary death as outcome remained and were included in the analysis.Citation11,Citation14,Citation18,Citation20Citation23,Citation25,Citation27,Citation30Citation32,Citation34,Citation36Citation50,Citation52,Citation54Citation56 As some articles described more than one cohort,Citation11 more than one subpopulation of a cohort (eg, men and women separately), and we included only one outcome measure per cohort (coronary events only, if coronary deaths were also reported), results for a total of 38 different populations were included in the analysis. These populations were categorized as patients without pre-existing CHD or as “high risk populations” – defined as patients with diabetes, pre-existing CHD, or the elderly – and into men or women or men/women within these categories. The cohorts included were: among populations without pre-existing CHD, 17 for men (Atherosclerosis Risk in Communities study [ARIC],Citation45 Canadian Community Health Survey [CCHS],Citation54 CMS,Citation30 CSCHDS,Citation52 CUORE,Citation23 FHS,Citation20 Göttingen Risk, Incidence and Prevalence Study [GRIPS],Citation18 Health Professional’s Follow-Up Study [HPFUS],Citation40 Lipid Research Clinics Coronary Primary Prevention Trial [LRC-CPPT],Citation11 Metabolic, Lifestyle, and Nutrition Assessment in Young Adults [MELANY],Citation55 MRFIT,Citation22 the second Northwick Park Heart Study [NPHSII],Citation48 Physician’s Health Study [PHS],Citation46 PROCAM,Citation14 Quebec Cardiovascular Study [QCVS],Citation39 Uppsala Longitudinal Study of Adult Men [ULSAM],Citation21 Western Collaborative Group Study [WCGS]Citation25), 2 for men/women (4CJ,Citation27 Asia Pacific Cohort Studies Collaboration [APCSC]Citation38), and 5 for women (ARIC,Citation45 CCHS,Citation54 FHS,Citation20 NHS,Citation44 Women’s Health Study [WHS]Citation56) with coronary events as outcome, and 3 for men (Apolipoprotein Mortality Risk Study [AMORIS],Citation50 LRC-FS,Citation11 ROGCitation36) and 3 for women (AMORIS,Citation50 Enlarged Waist with Elevated Triglycerides study [EWET],Citation49 LRC-FSCitation11) with coronary deaths as outcome; among high risk populations with coronary events as outcome, 1 with diabetes (KuopioCitation32), 5 with diabetes without pre-existing CHD (HPFUS,Citation31 ARIC,Citation42 SHS,Citation34 UKPDS,Citation47 NHSCitation43), 1 of the elderly without prior MI (CHSCitation41) or stroke, and 1 post-MI (THROMBOCitation37).

The primary outcome measure was a multivariate estimate of the statistical significance of the independent association between triglycerides and CHD, with HDL-C and other lipids (LDL-C, triglycerides, etc.) as explanatory variables. A secondary outcome measure was a univariate analysis of the statistical significance of the association between triglycerides and CHD, typically based on an ANOVA comparison of triglyceride concentrations in patients who did and did not subsequently experience CHD. CHD was classified as coronary events and coronary deaths. Outcomes described by authors as myocardial infarction (MI), CHD, or ischemic heart disease, were reclassified as coronary events.

Examination of the articles indicated that no consistent definition of the independent variable (triglyceride concentration) was applied and, in most reports of multivariate models of the association between triglycerides and CHD, a P value was the only information provided, frequently as P < 0.05 or nonsignificant (NS) (P > 0.05). Therefore, a descriptive approach was taken: we enumerated the number of cohorts in which triglycerides were or were not a significant independent predictor of CHD. We also summarized results by various study characteristics – the study population, study size (patient-years of follow-up), fasting status of patients at baseline lipid measurement, the type of multivariate model (proportional hazards models or unconditional multiple logistic regression), the definition of the independent variable (triglyceride concentration), and lipid variables included in the model. We took the median point for these variables and simply enumerated the number of cohorts above and below the median in which triglycerides were independently associated with the development of CHD. The number of patient-years of follow-up was as reported in the original articles or, if not cited, was calculated from the number of patients and the average years of follow-up; if the average years of follow-up was not reported, the study duration was used.

Results

Consistent association between triglycerides and CHD in univariate analyses

In univariate analyses of patients without pre-existing CHD, the plasma triglyceride concentration was significantly associated with CHD in 16 of 16 cohorts with coronary events as outcomeCitation11,Citation18,Citation21,Citation22,Citation25,Citation27,Citation30,Citation39,Citation40,Citation44Citation46,Citation48,Citation52,Citation56 and in 6 of 6 cohorts with coronary death as outcome.Citation11,Citation36,Citation49,Citation50 This was also the case in 5 of 5 studies of diabetic patients with coronary events as outcome.Citation31,Citation32,Citation34,Citation42,Citation43 In only one study, in which patients had a prior MI, were triglycerides not significantly associated with recurrent coronary events.Citation37 Representative relative risks (RRs) of coronary events, adjusted for matching demographic and other nonlipid factors, were RR 2.41 (95% CI 1.43–4.07) for men in the HPFUS cohort and 3.5 (1.8–7.3) for women in the NHS cohort (RR comparing the top and bottom quintiles of triglyceride levels).Citation40,Citation44

Inconsistent association between triglycerides and CHD in multivariate models including HDL-C

The pertinent results of multivariate analyses in which triglycerides, HDL-C, and other lipids were entered as independent variables are summarized in . The relationship between triglycerides and subsequent coronary events or coronary death was statistically significant in 16 instancesCitation14,Citation20,Citation22,Citation27,Citation30,Citation38,Citation45,Citation46,Citation48Citation50,Citation52,Citation54Citation56 (CCHS,Citation54 CMS,Citation30 CSCHDS,Citation52 MELANY,Citation55 MRFIT,Citation22 NPHSII,Citation48 PHS,Citation46 and PROCAMCitation14 for men; 4CJCitation27 and APCSCCitation38 for men/women; and ARIC,Citation45 AMORIS,Citation50 CCHS,Citation54 FHS,Citation20 EWET,Citation49 and WHSCitation56 for women) and not significant in 14 instancesCitation11,Citation18,Citation20,Citation21,Citation23,Citation25,Citation36,Citation39,Citation40,Citation44,Citation45,Citation50 (ARIC,Citation45 CUORE,Citation23 FHS,Citation20 GRIPS,Citation18 HPFUS,Citation40 LRC-CPPT,Citation11 QCVS,Citation39 ULSAM,Citation21 WCGS,Citation25 AMORIS,Citation50 LRC-FS,Citation11 and ROGCitation36 for men; and NHSCitation44 and LRC-FSCitation11 for women) in analyses of populations without pre-existing CHD. In studies of high risk populations, the relationship between triglycerides and subsequent coronary events was not statistically significant in any of the 8 cohorts.Citation31,Citation32,Citation34,Citation37,Citation41Citation43,Citation47

Table 1 Numbers of cohorts in which triglycerides were or were not predictive of CHD independently of HDL-C, by selected study characteristics

Although inconclusive, there is some indication that the association between triglycerides and CHD may be more frequently detectable among women and among populations without pre-existing CHD. Among populations without pre-existing CHD, triglycerides were significantly associated with CHD in 6 of 8 analyses of women,Citation20,Citation45,Citation49,Citation50,Citation54,Citation56 2 of 2 analyses of men/women,Citation27,Citation38 and 8 of 20 analyses of men.Citation14,Citation22,Citation30,Citation46,Citation48,Citation52,Citation54,Citation55 As indicated, the relationship between triglycerides and coronary events was significant in none of 8 high risk populations.

The association between triglyceride levels and subsequent coronary events was not correlated with cohort size in populations without pre-existing CHD. In 12 cohorts of between 6,835 and 50,848 patient-years, the association was significant in 6 cohorts; in 12 cohorts of 53,890 to 796,671 patient-years, the association between triglyceride levels and subsequent coronary events was significant in 8 (cohorts not listed).

In an analysis of the WHS, Bansal and colleagues recently argued that nonfasting but not fasting triglyceride levels were independently associated with cardiovascular events (fasting triglycerides were significantly predictive of coronary events when the proportional hazards model included as covariates age, blood pressure, smoking status, use of hormone replacement therapy, triglycerides, and HDL-C, but not when diabetes mellitus, body mass index, and high-sensitivity C-reactive protein were also added).Citation56 Referring to participants without pre-existing CHD, we observed that triglycerides were a significant independent predictor of coronary events in 6 of 6 populations with nonfasting blood samplesCitation27,Citation46,Citation48,Citation54,Citation56 and 9 of 19 instances with fasting blood samplesCitation14,Citation20,Citation22,Citation30,Citation38,Citation45,Citation49,Citation52,Citation55 (Patients in all analyses of high risk populations provided fasting blood samples).

Details of the multivariate modeling did not appear to affect whether triglycerides were significant. Both significant and nonsignificant associations between triglycerides and coronary events occurred in both proportional hazards models (9 significantCitation14,Citation22,Citation27,Citation38,Citation48,Citation54Citation56 and 3 nonsignificantCitation11,Citation21,Citation23) and multiple logistic regression models (3 significantCitation30,Citation46,Citation52 and 5 nonsignificantCitation18,Citation25,Citation39,Citation40,Citation44). The independent variable (triglyceride concentration) was entered into some models as a continuous variable, sometimes log-transformed; in other cases, triglyceride concentration was treated as a categorical variable, and divided into tertiles, quartiles, or quintiles. However, the definition of the triglyceride variable did not appear to affect whether triglycerides were significant (cohorts not listed). We also considered the lipid and nonlipid variables that were included in the models, but none of these factors appeared to vary systematically by triglyceride result. LDL-C, for example, was a significant independent variable in 10 studies with coronary events as dependent variable, among which triglycerides were significant in 4Citation14,Citation22,Citation30,Citation48 and nonsignificant in 6.Citation11,Citation18,Citation39,Citation40,Citation44,Citation57 In 6 other studies, in which total cholesterol was significant, triglycerides were significant in 4Citation27,Citation46,Citation48,Citation52 and nonsignificant in 2.Citation23,Citation25 And in 3 studies in which apolipoprotein B was significant, triglycerides were significant in 1Citation48 and nonsignificant in 2.Citation40,Citation57

Discussion

Statistically significant and quite strong negative correlations between triglycerides and HDL-C were reported in some of the cohorts analyzed, with values ranging from −0.26 to −0.58.Citation32,Citation38,Citation40,Citation44,Citation46,Citation51,Citation52,Citation56,Citation58,Citation59 Given this negative correlation, we considered whether triglycerides and HDL-C were mutually exclusive predictors of CHD. That is, we considered whether HDL-C and triglycerides were identified in the same multivariate model as independent predictors of coronary events. Of 20 analyses with coronary events as outcome for patients without pre-existing CHD, there were 6 instances in which HDL-C was a significant independent predictor of CHD but triglycerides were not, and 6 instances in which triglycerides were significant but HDL-C was not. There were 4 instances in which both triglycerides and HDL-C were significant independent predictors of CHD and 4 instances in which neither was significant. This suggests that a negative correlation between triglycerides and HDL-C may have obscured the relationship between triglyceride levels and risk of CHD.

Previously, investigators have taken a meta-analytic approach to determine whether triglycerides are significantly predictive of CHD independently of HDL-C.Citation8Citation10,Citation60 Beginning in 1996,Citation8 these authors concluded that triglycerides were a risk factor for cardiovascular disease in the general population, independently of HDL-C. A pooled, multivariable-adjusted RR, with respect to a 1 mmol/L increase in serum triglycerides, was reported as RR 1.14 (95% CI 1.05–1.28) for six studies of men and RR 1.37 (95% CI 1.13–1.66) for two of studies of women.Citation8 The most recent (2007) pooled analysis included 11 articles reporting multivariable adjustment for HDLC.Citation60 The meta-analytic approach, however, is limited by a dependence on reporting in the literature of data in a form suitable for statistical pooling. Given the variety of analytic approaches taken in the primary studies, statistical pooling across all studies depends on a process of assumption, inference, and imputation.Citation61 In contrast, our descriptive approach did not require any particular data reporting format and allowed analysis of a much larger data set of 32 articles reporting 38 cohorts.

The epidemiological data in the current analysis provide support for triglycerides as a predictor of CHD independently of HDL-C, but possibly only in certain categories of patient or level of CHD risk. Triglycerides were not independently predictive of CHD in 8 of 8 high risk cohorts, perhaps because the association between triglycerides and CHD is relatively weak and is outweighed by other factors in high-risk populations. Triglycerides were predictive of CHD independently of HDL-C in about half of the lower risk, primary cohorts. This may reflect random error and a relatively weak association that might fall on either side of the cut-point of P = 0.05 (The disadvantage of our descriptive approach is that it does not account for the numerical strength of an association, but simply whether it falls on either side of a cut-point). Consistent with these arguments, triglycerides were most often (in 6 of 8 cohorts) independently predictive of CHD in the lower-risk, primary populations of women.

The data also point to the inverse correlation of triglycerides and HDL-C in their role as risk factors. The inverse relationship between triglyceride and HDL-C levels likely reflects their respective participation in lipid transport and reverse cholesterol transport. The inverse relationship holds in the effects of lipid-modifying drugs. Niacin,Citation62 fibrates,Citation62 statins,Citation63,Citation64 CETP inhibitors,Citation65 and gemcabeneCitation66 all concomitantly increase HDL-C and decrease triglyceride levels. Certain genetic changes also have inverse effects on HDL-C and triglycerides. Mutations in ABCA1, a gene encoding a protein involved in cholesterol transport, result in lowered HDL-C and raised triglycerides levels, in conjunction with an increased risk of CHD.Citation67 Similarly, a mutation in the gene encoding lipoprotein lipase, and causing a lipoprotein lipase deficiency, decreases HDL-C levels, while increasing triglycerides levels and the risk of CHD.Citation68Citation71 The opposite effects are seen with a mutation in the lipoprotein lipase gene that results in increased enzyme activity: HDL-C is increased, while triglyceride levels and the risk of CHD are decreased.Citation72,Citation73 The inverse relationship does not seem to be absolute, however, since other genetic alterations indicate that the inverse relationship between HDL-C and triglyceride levels can be uncoupled. Subjects with an inherited hepatic lipase deficiency have hypertriglyceridemia in combination with increased HDL-C, associated with premature atherosclerosis and increased risk of CHD.Citation74Citation78 This suggests that the cardio-protective effect of elevated HDL-C is not seen in the absence of the inverse relationship with triglycerides.

Conclusions

Epidemiological evidence indicates that plasma triglyceride levels are predictive of CHD. The relationship between triglycerides and CHD is stronger and more consistently observed in populations without elevated CHD risk (eg, without pre-existing CHD). Population based screening for elevated triglycerides may identify individuals at elevated risk for CHD who may not otherwise be detected. Multivariate analyses indicate that the strong inverse relationship between triglycerides and HDL-C may reflect a common pathophysiologic process. This suggests that high triglycerides or low HDL-C or both might be considered for use in CHD risk estimation and that both triglycerides and HDL-C may be considered targets for therapeutic or lifestyle interventions.

Acknowledgements

The authors are grateful to Vasilisa Sazonov, PhD for inspiring this work, to Samantha Soldan, PhD and Victoria Stern for research and medical writing assistance, and to Baishali M. Ambegaonkar for helpful comments on the manuscript.

Disclosure

Merck and Co., Inc. provided funding for this study.

References

  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA200128524869711368702
  • British Cardiac Society, British Hypertension Society, Diabetes UKJBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practiceHeart200591Suppl 5v15216365341
  • ConroyRMPyoralaKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J200324987100312788299
  • Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary preventionEur Heart J19981914345039820987
  • De BackerGAmbrosioniEBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical PracticeEur Heart J20032416011012964575
  • WoodDADurringtonPMcInnesGJoint British recommendations on prevention of coronary heart disease in clinical practiceHeart199880SupplS129
  • Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic AssociationBMJ2000320705810710586
  • HokansonJEAustinMAPlasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studiesJ Cardiovasc Risk19963213198836866
  • AustinMAHokansonJEEdwardsKLHypertriglyceridemia as a cardiovascular risk factorAm J Cardiol1998814A7B2B9462597
  • Abdel-MaksoudMFHokansonJEThe complex role of triglycerides in cardiovascular diseaseSemin Vasc Med200223253316222622
  • AvinsALNeuhausJMDo triglycerides provide meaningful information about heart disease risk?Arch Intern Med200016019374410888968
  • AssmannGSchulteHRelation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster studyAm J Cardiol19927073371519522
  • AssmannGSchulteHvon EckardsteinAHypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged menAm J Cardiol1996771179848651092
  • AssmannGCullenPSchulteHSimple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) studyCirculation20021053101511804985
  • BaintonDMillerNEBoltonCHPlasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease StudiesBr Heart J1992686061355351
  • BosGDekkerJMNijpelsGHoorn Study. A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism – The Hoorn StudyDiabetologia2003469101612819906
  • BurchfielCMLawsABenfanteRCombined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic diseaseCirculation199592143067664423
  • CremerPNagelDMannHTen-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 menAtherosclerosis1997129221309105565
  • CriquiMHHeissGCohnRPlasma triglyceride level and mortality from coronary heart diseaseN Engl J Med1993328122058464432
  • D'AgostinoRBRussellMWHuseDMPrimary and subsequent coronary risk appraisal: new results from the Framingham studyAm Heart J2000139(2 Pt 1):2728110650300
  • DunderKLindLLagerqvistBCardiovascular risk factors for stable angina pectoris versus unheralded myocardial infarctionAm Heart J2004147502814999201
  • EberlyLEStamlerJNeatonJDRelation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart diseaseArch Intern Med200316310778312742806
  • FerrarioMChiodiniPChamblessLEPrediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equationInt J Epidemiol2005344132115659467
  • HaimMBenderlyMBrunnerDElevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) RegistryCirculation19991004758210430760
  • HulleySBRosenmanRHBawolRDEpidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart diseaseN Engl J Med1980302138397374696
  • IngelssonEArnlovJSundstromJNovel metabolic risk factors for heart failureJ Am Coll Cardiol20054620546016325042
  • IsoHNaitoYSatoSSerum triglycerides and risk of coronary heart disease among Japanese men and womenAm J Epidemiol2001153490911226981
  • JeppesenJHeinHOSuadicaniPRelation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male StudyArterioscler Thromb Vasc Biol1997171114209194762
  • JeppesenJHeinHOSuadicaniPTriglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male StudyCirculation1998971029369531248
  • JeppesenJHeinHOSuadicaniPLow triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart diseaseArch Intern Med2001161361611176761
  • JiangRSchulzeMBLiTNon-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetesDiabetes Care2004271991715277429
  • LaaskoMLehtoSPenttlaILipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetesCirculation199388(4 Pt 1):1421308403288
  • LehtoSRonnemaaTHaffnerSMDyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDMDiabetes199746135499231662
  • LuWResnickHEJablonskiKANon-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart studyDiabetes Care200326162312502653
  • MenottiASpagnoloAScangaMMultivariate prediction of coronary deaths in a 10 year follow-up of an Italian occupational male cohortActa Cardiol199247311201523912
  • MenottiAScangaMMorisiGSerum triglycerides in the prediction of coronary artery disease (an Italian experience)Am J Cardiol19947329328279373
  • MossAJGoldsteinREMarderVJThrombogenic factors and recurrent coronary eventsCirculation19999925172210330382
  • PatelABarziFJamrozikKSerum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific regionCirculation200411026788615492305
  • PirroMMauriegePTchernofAPlasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular StudyAtherosclerosis20021603778411849661
  • PischonTGirmanCJSacksFMNon-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in menCirculation200511233758316316964
  • PsatyBMAndersonMKronmalRAThe association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health StudyJ Am Geriatr Soc20045216394715450039
  • SaitoIFolsomARBrancatiFLNontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) StudyAnn Intern Med2000133819110896647
  • SchulzeMBShaiIMansonJEJoint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetesDiabetologia20044721293615662553
  • ShaiIRimmEBHankinsonSEMultivariate assessment of lipid parameters as predictors of coronary heart disease among post-menopausal women: potential implications for clinical guidelinesCirculation200411028243015492318
  • SharrettARBallantyneCMCoadySACoronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) StudyCirculation200110411081311535564
  • StampferMJKraussRMMaJA prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarctionJAMA199627688288782637
  • StevensRJKothariVAdlerAIThe UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)Clin Sci (Lond)2001101671911724655
  • TalmudPJHaweEMillerGJNonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK menArterioscler Thromb Vasc Biol20022219182312426225
  • TankoLBBaggerYZQinGEnlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal womenCirculation200511118839015837940
  • WalldiusGJungnerIHolmeIHigh apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective studyLancet200135820263311755609
  • WilsonPWLarsonMGCastelliWPTriglycerides, HDL cholesterol and coronary artery disease: a Framingham update on their interrelationsCan J Cardiol199410Suppl5b9b
  • YarnellJWPattersonCCSweetnamPMDo total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Ten-year follow-up of Caerphilly and Speedwell CohortsArterioscler Thromb Vasc Biol2001211340511498463
  • YuSYarnellJWSweetnamPHigh density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly StudyAtherosclerosis2003166331812535746
  • NordestgaardBGBennMSchnohrPNonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and womenJAMA200729829930817635890
  • TiroshARudichAShochatTChanges in triglyceride levels and risk for coronary heart disease in young menAnn Intern Med20071473778517876021
  • BansalSBuringJERifaiNFasting compared with nonfasting triglycerides and risk of cardiovascular events in womenJAMA20072983091617635891
  • DunderKLindLZetheliusBEvaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM)Am Heart J200414859660115459588
  • SweetnamPMBoltonCHDownsLGApolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly studyEur J Clin Invest2000309475611114956
  • DespresJPLemieuxIDagenaisGRHDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular studyAtherosclerosis20001532637211164415
  • SarwarNDaneshJEiriksdottirGTriglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studiesCirculation2007115450817190864
  • DaneshJCollinsRApplebyPAssociation of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studiesJAMA19982791477829600484
  • BirjmohunRSHuttenBAKasteleinJJEfficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trialsJ Am Coll Cardiol2005451859715653014
  • EdwardsJEMooreRAStatins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trialsBMC Fam Pract200341814969594
  • LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ2003326142312829554
  • DavidsonMHMcKenneyJMShearCLEfficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levelsJ Am Col Cardiol200648177481
  • BaysHEMcKenneyJMDujovneCAEffectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterolAm J Cardiol2003925384312943873
  • OramJFTangier disease and ABCA1Biochim Biophys Acta200015291–33213011111099
  • BenlianPEtienneJde GennesJLHomozygous deletion of exon 9 causes lipoprotein lipase deficiency: possible intron-Alu recombinationJ Lipid Res199536356667751824
  • BenlianPDe GennesJLFoubertLPremature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase geneN Engl J Med1996335848548778602
  • HokansonJEFunctional variants in the lipoprotein lipase gene and risk cardiovascular diseaseCurr Opin Lipidol199910393910554701
  • WittrupHHTybjaerg-HansenANordestgaardBGLipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysisCirculation1999992901710359734
  • ThornJANeedhamEWMattuRKThe Ser447-Ter mutation of the lipoprotein lipase gene relates to variability of serum lipid and lipoprotein levels in monozygotic twinsJ Lipid Res199839437419508003
  • GagneSELarsonMGPimstoneSNA common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring StudyClin Genet199955450410450862
  • BreckenridgeWCLittleJAAlaupovicPLipoprotein abnormalities associated with a familial deficiency of hepatic lipaseAtherosclerosis198245161796961921
  • HegeleRALittleJAVezinaCHepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristicsArterioscler Thromb19931372088485124
  • JiJHerbisonCEMamotteCDHepatic lipase gene -514 C/T polymorphism and premature coronary heart diseaseJ Cardiovasc Risk200291051312006918
  • HokansonJEKambohMIScarboroSEffects of the hepatic lipase gene and physical activity on coronary heart disease riskAm J Epidemiol20031588364314585761
  • RuelILCouturePCohnJSEvidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolismJ Lipid Res20044515283715175359